Pharma and healthcare: sector news on Thursday 12 November 2026
Average tone +2.2 (slightly positive) across 5 companies with relevant coverage, from 52 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +7.5 | 25 | Coverage was dominated by the acquisition of vaccine start-up Omniose, which was seen as strengthening its bacterial vaccine pipeline. |
| GSK | +4.5 | 12 | Coverage was dominated by GSK's patent wins against Pfizer and BioNTech over COVID vaccine technology, plus a settlement with Moderna. |
| Haleon | −3.3 | 7 | Coverage centred on analyst reaction to the lowered guidance following the third-quarter trading update, with RBC critical of the outlook but keeping a neutral rating. |
| Smith & Nephew | +0.8 | 5 | Coverage was mainly about the start of the second half of the company's $500 million share buyback, which is mildly positive. |
| Convatec | +1.7 | 3 | Coverage was mostly light commentary on Convatec from financial websites. |
Strongest stories in the sector
- +10.0 Broad analyst target increases after quarterly results.
- +10.0 Most analyst houses lifted targets after quarter.
- +10.0 Injunction covering many countries strengthens its patent position against rivals.
- +9.2 First conditional approval for kidney disease drug.
- +9.2 Won patent ruling against two major vaccine rivals.
- +8.3 Bolt-on deal strengthens bacterial vaccine work.
- +8.3 Deal reinforces bacterial vaccine pipeline.
- +8.3 Vaccine start-up purchase adds pipeline strength.
- +8.3 Gains a bioconjugation platform for vaccines.
- +8.3 Purchase offers simpler route to manufacture conjugate vaccines.
- +8.3 Acquisition aids vaccines against serious bacterial infections.
- +8.3 Core earnings rising again after results.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.